本報告已在2011年07月19日停止出版。
代謝症候群不僅是動脈硬化疾病及肥胖、胰島素抗阻性、高血壓的主因，也是脂肪代謝異常、2 型糖尿病的原因。一般認為美國病患人數已經突破4,000萬人次，並且預料在未來15年 內將會加倍成長，並帶給新興社會與經濟相當大的衝擊。
在調查基因與新藥等生命科學領域的最新技術與商業開發上，素有高度評價的Insight Pharma Reports（總公司：美國麻州） ，詳盡地調查與分析代謝症候群治療藥的美國市場，並有系統地出版綜合報告書“Metabolic Syndrome: Pipeline Analysis and U.S. Market Forecast”。
此報告書在下面的內容裡，除了評價肥胖、脂肪代謝異常、2 型糖尿病、高血壓市場藥與開發中醫藥；也提供最近商品週期的相互關係、開發中13醫藥的優弱勢、未來15年的美國市場預測等的情報。此報告書的概略架構如下所示。
1. 說明
- 代謝症候群：多樣的症候群
- 疾病學：肥胖相關糖尿病
- 續論：內皮功能障礙、發炎、精神障礙
- 國立衛生研究所的ATP(成人治療)準則
2. 疾病學局面
- 過重/肥胖與運動不足
- 胰島素抗阻與糖尿病
- 高血壓、脂肪代謝異常
- 代謝症候群罹患率預測
3. 藥物療法的現況
- 生活方式改善的限度
- 疾病的藥物療法(胰島素抗阻性、糖尿病、胰島素增敏劑、脂肪代謝異常(Fibrates、Statins、Niaspan)、高血壓、體重減量劑)
4. 代謝症候群尚待解決課題
- 醫藥與治療計畫現況的尚待解決課題
- 遺傳性疾病素質與訂做醫療
- 新研究：神經營養因子的重要性
- 摘要
5. 未來改善-是否能有新突破？
- 針對體重減量的藥物治療策略
- 胰島素抗阻性與糖尿病治療的未來
- 脂肪障礙治療領域的新開發
- 高血壓治療的未來
- 通風治療的未來改善
6. 美國代謝症候群疾病市場的未來預測(2003-2018)
- 脂肪代謝異常治療的美國市場預測
- 2 型糖尿病治療的美國市場預測
- 肥胖治療的美國市場預測
- 高血壓治療的美國市場預測
7. 代謝症候群治療藥的研究開發狀況(主要13家)
- 7.1. Sanofi-Aventis
- 7.2. Eli Lilly
- 7.3. Novo Nordisk
- 7.4. Bristol-Myers Squibb
- 7.5. GlaxoSmithKline
- 7.6. Roche
- 7.7. Merck ＆ Co./Banyu
- 7.8. DeveloGen
- 7.9. Wellstat
- 7.10. Amylin Pharmaceuticals
- 7.11. Ligand Pharmaceuticals
- 7.12. Regeneron Pharmaceuticals
- 7.13. Biovitrum
Abstract
Metabolic Syndrome: Pipeline Analysis and U.S. Market Forecast is a thorough
evaluation of marketed therapies and drugs in development for obesity,
dyslipidemia, type 2 diabetes, and hypertension.
Metabolic Syndrome is a cluster of risk factors for atherosclerotic disease
and type 2 diabetes mellitus comprising obesity, insulin resistance,
hypertension, and dyslipidemia. The eligible treatment population in the U.S.
for these four conditions is currently 40 million patients and will nearly
double over the next 15 years, bringing unprecedented social and economic
impacts.
Specifically, this report:
- Reveals the latest findings about the interactions among widely prevalent
lifestyle factors such as poor nutrition, being overweight, and sedentary
lifestyle, and how they contribute to insulin resistance, dyslipidemia, and
high blood pressure.
- Assesses the strengths and weaknesses of 13 R&D pipelines focused on
metabolic syndrome, comparing products and mechanisms in each disease
category against one another and against the gold standard.
- Presents 15-year forecasts of sales in the U.S. of marketed and
investigative therapies for each of the four disorders, taking into account
unmet medical need, changes in epidemiology, patent expirations, and
competitive drug launches.
- Spotlights the most promising drugs and early-stage mechanisms of action
and the likely timeframe for their launch.
Decision makers in early-stage development are waking up to the need for
solid market intelligence about competitor projects and the commercial potential
of products in development. Forecasts are taking a central role in the
commercial assessment of early-stage drug therapies, where they can serve as the
repository of a companys latest thinking on both commercial and clinical
questions. Through a reliable, early-stage forecast and an assessment of
products in development, Metabolic Syndrome: Pipeline Analysis and U.S. Market
Forecast provides R&D managers with the clinical data, the analytical tools,
and the market intelligence they need to make informed decisions about
individual projects and portfolios.
Table of Contents
Chapter 1: Introduction
- 1.1. Metabolic Syndrome: A Multifaceted Syndrome by Many Names
- 1.2. Etiology of Primary Components: The Vicious Cycle of "Diabesity"
- 1.3. Further Sequels: Endothelial Dysfunction, Inflammation, and
Psychiatric Implications
- 1.4. The National Institutes of Health ATP III Guidelines and Definition
Chapter 2: Epidemiological Aspects
- 2.1. Overweight/Obesity and Lack of Physical Activity
- 2.2. Insulin Resistance and Diabetes
- 2.3. Elevated Blood Pressure and Hypertension
- 2.4. Dyslipidemia
- 2.5. Estimates for Prevalence and Incidence of the Metabolic Syndrome
Chapter 3: Current Options for Pharmacological Intervention
- 3.1. Limited Potential for Lifestyle Modifications
- 3.2. Current Pharmacological Treatment of Component Entities
- Drugs for Insulin Resistance and Emerging Type 2 Diabetes
- -Sulphonylureas--Stimulators of Basal Insulin Release
- -Post-Prandial Insulin Secretion Stimulators--the "Meglitinides"
- Insulin Sensitizers
- -Metformin (Bristol-Myers Squibbs glucophage/glucamet; generics)
- -Glitazones--The Original PPAR Agonists
- --Avandia (rosiglitazone maleate, GlaxoSmithKline)
- --Actos (pioglitazone HCl, Eli Lilly and Takeda)
- -Glitazone/Metformin Fixed Combination Products
- -Alpha-Glucosidase Inhibitors: Intestinally Acting Glucose Retardants
- Drugs for Dyslipidemia: Fibrates, Statins, and Niacin
- -Fibrates
- --Lopid (Pfizers gemfibrozil and generics)
- --TriCor/Lipanthyl/Lipidil (fenofibrate, Abbott Laboratories and
Groupe Fournier; generics)
- --Bezalip (Roches bezafibrate)
- --Lipanor/Modalim (Sanofi-Aventis ciprofibrate)
- -Statins
- -Cholesterol Absorption Inhibitors
- --Ezetimibe (Schering-Plough/Merck & Co.s Zetia)
- -Niaspan and Advicor
- Hypertension: Drug Class Differences in the Metabolic Effects
- Weight Reduction Agents
- -Xenical (orlistat, Roche)
- -Meridia/Reductil (sibutramine, Abbott Laboratories)
- -"Short-Term Slimmers": No Relevance to the Metabolic
Syndrome
Chapter 4: Unmet Treatment Need in the Metabolic Syndrome
- 4.1. Unmet Need in Current Drugs and Treatment Schedules
- Weight Reduction Drugs
- Glucose-Lowering Drugs
- Lipid-Lowering Drugs
- Anti-Hypertensive Drugs
- 4.2. Genetic Predisposition and Tailored Therapies: A Great Task Ahead
- 4.3. Unconventional Approaches: A Role for Neurotrophic Factors?
- 4.4. Summary
Chapter 5: Improvements Ahead--Breakthroughs on the Horizon?
- 5.1. Pharmacological Strategies to Support Weight Loss: A Bumpy Road
- Regenerons Axokine: A Nerve Growth Factor Agonist Completing Clinical
Development
- Acomplia (rimonabant) and Other CB1 Receptor Antagonists for Slimming
- New Pancreatic Lipase Inhibitors in the Pipeline
- Symlin (Pramlintide acetate, an Analog of Amylin)
- An Appetite Suppressant from a South African Cactus
- Targeting the Adrenergic System--Adjusting the Metabolic Rate
- 5-HT2c Receptor Agonists
- Neuropeptide Y Receptor Agonists
- Melanocortin Receptor Agonists
- 5.2. Potential Treatments for Insulin Resistance and Diabetes
- Dual PPAR Stimulators--A New Class of Drugs Tailored to Metabolic
Syndrome Therapy
- Dipeptidyl Peptidase Inhibitors--Blocking Degradation of Glucagon-
Like Peptide 1
- Glucagon-Like Peptide Analogs
- Sodium-Dependent Glucose Co-Transporter (SGLT) Inhibitors
- An Antisense PTP-1B Gene Silencer
- 5.3. New Developments in Lipid Disorders
- Cholesteryl Ester Transfer Protein (CETP) Inhibitors
- Ibrolipim: A Lipoprotein Lipase Activator
- An Antibody Mix for Dyslipidemia
- Inhibition of Acetyl-CoA Carboxylase
- Antisense Drugs
- Omacor, an FDA-Approved Nutritional Supplement
- 5.4. Targeting Hypertension in the Metabolic Syndrome
- Renin Inhibitors
- Selective Aldosterone Blockade
- Endothelin A Receptor Antagonists
- 5.5. Potential Improvements in the Therapy of Gout
Chapter 6: U.S. Market Forecast for Metabolic Syndrome Component
Disorders: 2003-2018
- 6.1 United States Market Forecast for Dyslipidemia
- Market Overview
- Patent Expirations
- Drug Launches
- Epidemiology
- 6.2. United States Market Forecast for Type 2 Diabetes
- Market Overview
- Patent Expirations
- Drug Launches
- Epidemiology
- 6.3. United States Market Forecast for Obesity
- Market Overview
- Patent Expirations
- Drug Launches
- Epidemiology
- 6.4. United States Market Forecast for Hypertension
- Market Overview
- Patent Expirations
- Drug Launches
- Epidemiology
Chapter 7: Pipeline and Research Program Profiles
- 7.1. Sanofi-Aventis
- 7.2. Eli Lilly
- 7.3. Novo Nordisk
- 7.4. Bristol-Myers Squibb
- 7.5. GlaxoSmithKline
- 7.6. Roche
- 7.7. Merck & Co./Banyu
- 7.8. DeveloGen
- 7.9. Wellstat
- 7.10. Amylin Pharmaceuticals
- 7.11. Ligand Pharmaceuticals
- 7.12. Regeneron Pharmaceuticals
- 7.13. Biovitrum
